GRAL +6.01% NVDA -0.52% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
It always makes sense to look at the downside risk as well as the upside potential in a stock, and that's particularly the case with a speculative growth stock like a multi-cancer early detection (MCED) test company, Grail (NASDAQ: GRAL). While most of the debate, quite correctly, centers on a binary event (FDA approval of its Galleri test) and then on whether medical insurers cover the test, there's another huge consideration: its pricing.
The company received a boost recently with news that the FDA's Medical Devices Advisory Committee's Molecular and Clinical Genetics Devices Panel voted in favor of Galleri's safety, benefit, and effectiveness, paving the way for FDA marketing approval.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
The news sent the stock soaring (up 80% in the past month) and raised hopes that subsequent FDA approval would open the door to discussions with medical insurers and bodies about adopting the Galleri test.
For those interested in a summary of some of the cost-benefit considerations potential insurers will weigh regarding Galleri, I've discussed them previously. It's always interesting to consider matters in binary terms, such as FDA approval or not. Or will medical insurers adopt?
The key decision regarding adoption involves weighing the benefits of Galleri's ability to detect cancers earlier (leading to better patient outcomes and less expensive, less painful late-stage treatment) against factors such as its cost and the number of false positives it produces (which can lead to expensive, unnecessary follow-up testing).
The key debate may not be about adoption or non-adoption, or even about the rate of adoption; it may boil down to the price insurers and medical bodies are willing to pay. That price will largely depend on the cost-benefit calculations insurers make, which in turn depend on the clinical data Grail can present. It's not simply a question of FDA approval, or even a willingness to adopt Galleri; it comes down to what test price insurers are willing to pay.
This is a key risk factor that investors need to consider for a test with a current list price of $949.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Grail wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $379,123!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,408,822!*
That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.
*Stock Advisor returns as of October 11, 2026.
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Grail. The Motley Fool has a disclosure policy.
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore. was originally published by The Motley Fool
